CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Tacrolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01977781
NCT01977781Phase 1Completed
CompareCT.gov

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

Massachusetts Eye and Ear Infirmary·interventional·Posted Nov 7, 2013·Updated May 15, 2017

In Brief

A Phase 1 clinical trial evaluating Tacrolimus and Methylprednisolone Sodium Succinate for Ocular GVHD. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of topical tacrolimus 0.05% twice a day in the treatment of ocular graft versus host disease (GVHD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular GVHD
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 7, 2013
Enrollment StartDec 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.7 years ago

Interventions

Tacrolimusdrug

Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks

Methylprednisolone Sodium Succinatedrug

Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks